TKM-Ebola-Guinea: Phase II data

Tekmira stopped enrollment in the open-label, African Phase II RAPIDE trial in patients with Ebola virus infection after a pre-defined futility analysis of the primary endpoint of mortality at day 14 showed that once-daily 0.3 mg/kg IV TKM-Ebola-Guinea for 7 days “was not likely to demonstrate an overall therapeutic benefit.” The trial was sponsored by the University of Oxford and was slated to enroll 100 patients. ...